H epatocellular carcinoma ( HCC ) is one of the most common cancers worldwide with an estimated 1 million new cases diagnosed each year. 1 Geographically, HCC clusters in areas such as Africa, South East Asia, and the Middle East where hepatitis infection is endemic. Chronic hepatitis B infection, hepatitis B carrier status, 2 and to a lesser degree hepatitis C infection all confer an increased risk of developing HCC. 3 This is primarily as a result of integration of viral DNA into the genome with consequent mutations of tumor suppressor genes such as p53. 4 The prognosis of HCC is poor with only a few patients surviving beyond 1 year. Curative options are either liver resection or liver transplantation. 5 Surgical resection can achieve up to a 50% 5 -year survival. 6 However, in most patients the tumors are unresectable because of their multicentricity or poor hepatic function. Systemic chemotherapy and/ or radiotherapy do not offer survival advantage.
For patients who are unsuitable candidates for potentially curative surgery, percutaneous ethanol injection (PEI ) and transarterial chemotherapy, with or without embolization, could be beneficial and slow the progression of the tumors. 7 Hyperthermia resulting from laser beam or radiofrequency heat ablation using cooled -tip needles have been used to provide palliation in these patients. 8, 9 Genetic abnormalities seen in HCC tumor cells include inactivation of tumor suppressor genes 10 and activation of oncogenes. 11 The tumor suppressor gene of most interest is p53 that is located on the short arm of chromosome 17 ( 17p13 ). Deletions or mutations of wild -type p53 have been identified in approximately 50% of all tumor types and its presence in HCC indicates a poorer prognosis. 12 In 1996 Bischoff and colleagues 13 identified the use of a mutant adenovirus (ONYX -15 ) that selectively replicates in tumor cells deficient in wild -type p53. This adenovirus is a hybrid of serotypes 2 and 5 with a deletion of the E1B region causing loss of expression of the 55-kDA viral protein. The virus was originally produced by Barker and Berk in 1987 14 and is known as dl1520. In this manuscript, the virus will only be referred to by its original name, dl1520. The presumed mechanism of tumor specificity is as follows. The dl1520 virus cannot replicate in normal cells endogenously expressing p53 gene, because p53 protein in such cells can inhibit the progression from G1 to S phase. As the virus is defective, viral replication cannot proceed. However, in tumor cells devoid of endogenous wild -type p53 gene the cell cycle check point is abolished, entry of cells into S phase is not blocked, and dl1520 virus is able to replicate. Following preclinical research, our group performed a phase I study of hepatic artery injection of dl1520 in patients with primary and secondary liver tumors. 15 Here we report the results of a phase II study in 10 patients with unresectable HCC treated with either dl1520 or with PEI.
Materials and methods

Adenovirus
The adenovirus used was dl1520 ( donated by Professor Berk, CA ). dl1520 has an 827 base -repair deletion in the region encoding the E1B 55-kDA protein in combination with a stop codon to ensure that the truncated 55-kDA product cannot be expressed. The adenovirus was manufactured to Good Manufacturing Practice grade by Magenta ( Sterling, Scotland) and its doses were expressed in plaque -forming units ( PFU ) where one plaque is equivalent to 20 particle -forming units.
Patients
The study was performed at Kasr El -Eini Hospital in Cairo, Egypt, following approval by the Scientific and Ethical Committee of Cairo University Medical School. All patients included in the study had HCC, which in Egypt is routinely treated with ethanol injection. Between November 1998 and August 1999, 10 patients ( 8 male and 2 female ), median age of 59 years ( range 46 -74 years ), with histologically proven HCC were enrolled in the study ( Table 1 ). All patients had posthepatitis liver cirrhosis classified as Child B in 2 patients and Child A in 8 patients.
Viral seromarkers for hepatitis B virus (HBV ) and hepatitis C virus ( HCV ) revealed that three patients were hepatitis B virus surface antigen (HBsAg) positive, all were hepatitis B virus antibody (HBAb ) negative, seven were hepatitis C virus antibody (HCAb) positive and three patients were negative for both HBAb and HCAb (Table 1) .
Study design
This was an open label, randomized, prospective study. Patients were randomized to receive either PEI or dl1520 gene therapy to treat their liver tumors. The group of patients treated with ethanol injection served as control (C ) to the treatment group (T ).
Inclusion criteria
Patients included in the study had to fulfill the following entry criteria: histological diagnosis of HCC with no more than two tumors; between 35 and 75 years of age; life expectancy of at least 3 months; adequate performance status ( Karnofsky score >70% ); laboratory data, white blood cell count ( WBC ) >3000 / L, platelet count >50,000 /L, hematocrit (HCT ) >25%, prothrombin time (PT ) < 20 seconds ( control 15 seconds ), creatinine 1.8 mg /dL, total bilirubin (Bil ) < 5 mg /dL, aspartate transferase ( AST ) and alanine transferase (ALT ) < 10 times upper limit of normal ( normal levels 40 IU /L ).
Before signing an informed consent document, a patient information leaflet was given to each patient, which explained the experimental nature of the study, risks involved and the unlikelihood of potential benefit to the individual.
Exclusion criteria
Patients with any of the following exclusion criteria were not included in this study: pregnant women; fertile patients unless using effective contraception for at least 1 month before study entry; uncontrolled serious bacterial, viral, fungal or parasitic infection; systemic corticosteroid therapy or other immunosuppressive therapy administered within the last 3 months.
Prestudy evaluation
Before administration of either treatment each patient had a medical history taken and a complete physical examination performed, including performance status (Karnofsky score ). Blood was taken for laboratory screening, which included full blood count (FBC ), profile, liver function tests ( LFTs), and hepatitis screen. Radiology screening included chest Xray and an abdominal computed tomography (CT ) scan. An ultrasound guided biopsy of the focal hepatic lesion was performed for histopathologic examination and anti-p53 immunohistochemical study. Serum samples were taken to detect the presence of adenovirus and anti -adenovirus antibodies. The tumors were in the right lobe in eight patients and in the left lobe in 2. Two patients with more than one lesion ( all in the right lobe ) showed p53 overexpression ( Table 2) .
Patients enrolled in the ethanol ( control ) group
Sterile 95% ethanol was administered with an 18 -to 20 -gauge spinal needle using the Livraghi technique. 
T, treatment group; C, control group; HbsAg, hepatitis B surface antigen; HBAb, hepatitis B antibody; anti -HCAb, antihepatitis C antibody.
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The dl1520 adenovirus was given as an intravenous injection in the arm vein (vena mediana cubiti ) for the first dose (day 1), then by direct intratumoral injection under ultrasound guidance on days 2, 15, 16, 29, and 30. The rationale for the first dose given intravenously was to increase the antibody titer to the adenovirus in order that the following intratumoral injections are accompanied by a local immunological reaction in the tumor.
The vector was given using local anesthesia and patients were carefully observed in hospital for a 2 -hour period following the treatment. All given doses were 1 mL in volume and contained 3Â10 11 PFU of dl1520 that had been found to be well tolerated in our previous phase I study. 15 
Posttreatment monitoring
Immediate posttreatment monitoring included physical examination, performance status and repeated laboratory investigation. Whenever patients' condition allowed, a liver biopsy or fine needle aspiration biopsy was performed 2 weeks after the treatment schedule had been completed.
Evaluation of efficacy of treatment
The following data on each patient enrolled in the study were analyzed 2 weeks after cessation of treatment: physical examination, including performance status; laboratory screening: FBC, total serum protein, albumin, AST, ALT, Bil, PT, alpha fetoprotein, CT scan of abdomen and pelvis. Evaluation of CT scan was recorded as follows: complete response (CR ), meaning complete disappearance of all evidence of disease lasting longer than 28 days; partial response ( PR ) meaning more than 50% reduction in the sum of the products of the perpendicular diameter for more than 28 days; minor response ( MR), meaning 25 -50% reduction in the sum of the products of the perpendicular diameter for more than 28 days; stable disease ( SD ), was considered as neither CR, PR nor MR or progressive disease; progressive disease (PR ), meaning more than 25% increase in the sum of products of perpendicular diameter or appearance of new lesions; and mixed response, indicating simultaneous progression yet regression of measurable lesions or other indices of response.
Liver function tests
LFTs were assessed according to the following criteria: a minimal rise in liver enzyme levels was considered to be an elevation of more than 10 U /mL after treatment; a mild rise in liver enzymes to be more than 20 U /mL after treatment; and a severe rise to be more than 100 U /mL after treatment.
Anti -adenovirus type 5 antibody titer
Anti-adenovirus type 5 antibody titer was measured preinjection and 10 days after dl1520 treatment. The serum was sent to a commercial laboratory ( Virolab, Berkeley, CA ) for analysis.
Analysis of adenovirus presence in serum samples using polymerase chain reaction ( PCR )
Blood samples were drawn at the following time intervals: preinfection and at 30 minutes, 1 hour, 4 hours, 10 hours, 24 hours, and 10 days to determine the presence of viral sequences in the blood by PCR. Blood serum from each sample was mixed with an equal volume (250 l) of lysis buffer containing 0.1 M TRIS (hydroxymethyl aminomethane, pH 7.5), 10 mM EDTA, 0.5% wt /vol sodium dodecyl sulfate (SDS ), and Proteinase K ( 1 mg /mL ) and was incubated at 378C overnight. DNA was partially purified by extraction with phenol:chloroform:isoamyl alcohol (24:24:1, pH 9.0 ) and alcohol precipitation. Precipitated DNA was resuspended in 150 l TE and quantified using ultraviolet spectrophotometry. Positive control DNA was extracted in a similar manner from purified human adenovirus 5.
Tumor tissue was homogenized in lysis buffer and incubated at 378C overnight. DNA was partially purified and quantified as described above. Before use, DNA preparations were stored at À 208C.
PCR primers were designed to amplify an 850-bp sequence corresponding to a gene encoding a human adenovirus 5 capsid structural protein utilizing sequence 
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Transmission electron microscopy of tumor tissue
Samples not exceeding 1 mm 3 in volume, were fixed in 2% glutaraldehyde for 2 hours. After washing in phosphate buffer, tissues were osmicated and dehydrated in acidified 2,2 dimethoxypropane (DMP ) before routine embedding in Taab 1 resin. One -micrometer sections were cut and stained with toluidine blue for observation at light microscope level and selection of relevant blocks, followed by ultrathin sections of approximately 100 nm, collected on nickel grids and stained with uranyl acetate and lead citrate, for observation on a Philips CM -10 electron microscope operated at 80 kV.
Results
Toxicity and complications
Ethanol -treated group. Complications reported following PEI included pain and fever. Intramuscular administration of nefopam hydrochloride (30 mg ) controlled the pain for the first 24 to 48 hours. Fever was reported in two patients, a mild episode of which was reported in one patient lasting for a few hours only; a fever of 398C lasting for 2 hours was reported in another patient. None of the patients experienced hypotension. Rigors were reported in three patients that mostly were associated with fever (Table 3) . dl1520 -treated group. None of the patients experienced pain. However, three patients reported fever ( 398C ) with rigors that developed 3 to 4 hours post treatment and resolved within 12 to 48 hours. Fevers were treated with cold foments or oral paracetamol (500 mg ). This complication occurred with each injection, but did not increase in severity. Hypotension occurred in 2 patients after the first or fourth intratumoral injections, respectively. Blood pressure returned to normal within 1 hour after treatment was completed. The Table 5 Liver function tests before and 2 weeks after treatment After ( % )   T1  80  80  T2  100  100  T3  90  90  T4  100  100  T5  90  90   C1  90  90  C2  80  50  C3  90  50  C4  90  90  C5  90  80 T, treatment group; C, control group. 
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Ethanol -treated group. In patients allocated to the control group one patient showed a marked rise in both AST ( pre: 85 IU /L; post: 499 IU /L ) and ALT levels (pre: 40 IU /L; post: 258 IU / L )), a rise in the level of Bil ( pre: 0.4 mg /dL; post: 1.14 mg /dL). A further patient showed a marked rise in the AST and ALT levels (AST 109 -249 IU /L; ALT 77 -611 IU /L ), but no change in Bil or albumin levels. The remainder of the control group showed no significant rise in liver enzyme levels or any marked effect on liver function ( PT, Bil and albumin ).
No significant changes in liver enzymes, PT, or albumin were observed in either the treatment or control groups ( Table 5) . dl1520 -treated group. Assessment of LFTs in the adenovirus -treated group revealed no significant rise in liver enzymes or marked effect on LFTs ( PT, Bil, Albumin ) in patients receiving treatment with dl1520. Two patients had a minimal rise in AST level and two patients had a mild rise in Bil.
Detection of antibodies
The mean level of anti -adenovirus type 5 antibody detected in the treatment group was 16 times higher at day 10 following the adenovirus injection compared to preinjection serum levels. This was statistically significant ( P= .0015 ) and was indicative of the recent adenoviral infection ( Table 6 ).
Detection of adenovirus type 5 sequence using PCR
Three patients showed no virus in the preinfected sample. However, there was a significant presence of adenoviral genome in the blood at 30 minutes, the earliest time point analyzed, these viral sequences disappeared rapidly and were undetectable after 4 hours.
Analysis of tissue biopsies using transmission electron microscopy ( TEM )
Ultrastructural pathology by TEM revealed tissue and cell morphology of the HCCs in this study, thus the presence of E1B -deleted viruses in the appropriately treated tumors; no ethanol -treated specimens were sampled for electron microscopy. Viral particles were detected in extracellular locations, at plasmamembranes, through the depth of cytoplasm, in juxtanuclear positions and intranuclearly ( Fig 1 ) .
Tumor response
Ethanol -treated group. Two patients remained with stable disease and the rest had progressive disease. dl1520 -treated group. There was a partial response in one patient with marked reduction in tumor volume from 306 to 22.5 cm 3 and a concomitant decrease in AFP level from 7604 to 300 ng /mL ( Table 7 ) . The remaining four patients demonstrated progressive disease with an increase in both tumor volume and AFP levels.
Discussion
HCC affects about 1 million new patients each year 1 and most patients present with tumors that are unresectable. Current therapies are largely ineffective 17 and median survival is less than 6 months.
This study evaluated the novel strategy of injection of dl1520 virus in patients with HCC and compared it with patients receiving standard therapy of direct ethanol injection into the tumor. One important outcome was that the virus was well tolerated when given in multiple doses. It has been reported 18 that neutralizing anti -adenovirus antibody rises sharply in serum after treatment with dl1520 and remains elevated throughout the treatment process and this was observed here. All patients had elevated anti -adenovirus antibodies before adenovirus therapy, which rose further significantly after treatment. Despite this, we observed no major vector-related toxicity even after repeated injections. There were no anaphylactic reactions and all toxic effects 
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Transient fever has been previously reported as an adverse event after intratumoral injection of adenovirus in non-small cell lung cancer 18, 19 and this finding was similar to our study. Pain was not reported at the injection site here, even though Clayman et al 20 and Swisher et al 19 observed this as the most common adverse event after intratumoral injection. All patients who had PEI suffered some pain but this had resolved within 24 to 48 hours.
A maximum dose of 3Â10 11 PFU was given here, which is still below the dose reached of 10 12 PFU that had been injected into the pleural sac for treatment of mesothelioma by Sterman et al. 21 Our five patients who were given dl1520 virus were treated as outpatients and were discharged from hospital on the day of treatment.
In dl1520 -treated cases, presence of adenovirus was established by electron microscopy. The specific agents were readily identified as therapeutic adenoviruses, not hepatitiscausing viruses by their morphology. 22 Statistical relationships between viral load and cell death in HCC was not undertaken in this investigation, but cell deletion after such treatment has previously been reported. 15 Our results showed partial response in only 1 patient with the remaining four patients demonstrating disease progression. Clayman et al 20 noted partial regression in 2 of 17 patients with recurrent head and neck carcinoma who were given wild -type p53 virus. Swisher et al 19 observed partial response in 2 of 25, stable disease in 16 of 25 and progressive disease in 7 of 25 patients.
To our knowledge, this is the first investigation to assess safety and tumor response of dl1520 in the treatment of HCC, and the vector was well tolerated in patients, although antitumor activity was modest. Future combination therapies including novel vectors or chemotherapeutic agents might improve the limited antitumor activity of the technique.
In conclusion, these results have suggested that injection of adenovirus mutant dl1520 is well tolerated by patients and further trials should be carried out to determine a more effective therapy, perhaps in combination with other modalities in treating patients with HCC.
